Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 5/20 | 0.62 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440135 | 0.82 | ENPP3 (0.62) | ENPP3ENPP1S1PR1S1PR3TP53 | |
| SCHEMBL22918669 | 0.82 | ENPP3 (0.62) | ENPP3ENPP1S1PR1S1PR3TP53 | |
| SCHEMBL24415640 | 0.79 | ENPP3 (0.69) | ENPP3ENPP1TP53MAPTTHRB | |
| SCHEMBL12112408 | 0.79 | ENPP3 (0.96) | ENPP3ENPP1TP53THRBPOLB | |
| SCHEMBL28025185 | 0.78 | ENPP3 (0.72) | ENPP3ENPP1S1PR1S1PR3TP53 | |
| Ammonia Solution, Strong SCHEMBL28862464 | 0.77 | ENPP3 (0.92) | ENPP3ENPP1TP53MAPTTHRB | |
| SCHEMBL16202266 | 0.77 | S1PR1 (0.74) | ENPP3ENPP1S1PR1S1PR3 | |
| SCHEMBL8117354 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53THRBPOLB | |
| SCHEMBL1169116 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53THRBPOLB | |
| SCHEMBL2056109 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2016009297-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | ENPP3 1766/4885ENPP1 1139/4885S1PR1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.